Actively Recruiting
Study On the Expression Level and Clinical Significance of VISTA in Patients With Vascular Cognitive Impairment
Led by First Affiliated Hospital of Harbin Medical University · Updated on 2024-04-02
400
Participants Needed
1
Research Sites
296 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
1\. Explore the expression level of immune checkpoint VISTA in peripheral blood and cerebrospinal fluid of patients with cardiovascular risk factors; 2. Discuss the correlation between different risk factors (mainly hypertension, diabetes, smoking, hyperlipidemia, hyperhomocysteinemia, etc.) and the expression level of immune checkpoint VISTA in peripheral blood and cerebrospinal fluid of patients with cerebrovascular diseases and immune-inflammatory related diseases of the nervous system; 3. Explore the correlation between different immune inflammatory factors (IL1, IL6, IL10, INFγ, TNFα) and the expression level of immune checkpoint VISTA in peripheral blood and cerebrospinal fluid of patients; 4. Track and explore the dynamic changes of immune checkpoint VISTA in peripheral blood and cerebrospinal fluid of patients with cardiovascular risk factors in 3 months, 1 year, 3 years, and 5 years.
CONDITIONS
Official Title
Study On the Expression Level and Clinical Significance of VISTA in Patients With Vascular Cognitive Impairment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants include 100 subjects: 50 with vascular cognitive impairment (VCI) and 50 normal controls
- VCI diagnosis based on the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders
- Informed consent obtained from all participants and their families for examinations and cognitive tests
You will not qualify if you...
- Exclusion according to Chinese guidelines for vascular cognitive impairment treatment 2019
- Presence of autoimmune diseases, blood diseases, malignant tumors
- Heart, liver, or kidney dysfunction
- Infectious diseases, family genetic diseases, recent acute or chronic inflammatory diseases
- Recent myocardial infarction
- Taking antibiotics, steroids, or immunosuppressants before the trial
- History of cranial trauma or brain surgery
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China, 150010
Actively Recruiting
Research Team
D
Dan Liu
CONTACT
L
LiJun Chi
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here